Monopar Therapeutics Inc. (MNPR)Healthcare | Biotechnology | Wilmette, United States | NasdaqCM
56.22 USD
-1.48
(-2.565%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 56.60 +0.38 (0.676%) ⇧ (April 17, 2026, 5:20 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:03 p.m. EDT
Monopar Therapeutics Inc. (MNPR) shows a mixed outlook. In the short term, the stock has been volatile with recent price fluctuations, and the forecasting model suggests a potential decline of around 7.5% over the next 45 days, indicating caution for short-term traders. The stock is currently trading below its 50-day and 200-day moving averages, which may signal a bearish trend. Long-term investors might find the current price attractive given the stock's potential in the biotechnology sector, but the company's negative earnings and high overall risk suggest that it is not a stable investment. There are no dividend payouts, making it unsuitable for income-focused investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.102472 |
| AutoETS | 0.184115 |
| AutoARIMA | 0.186270 |
| MSTL | 0.202397 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.443 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.178 |
| Market Cap | 376,232,128 |
| Forward P/E | -14.96 |
| Beta | 1.66 |
| Website | https://www.monopartx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.31631935 |
| Address1 | 1,000 Skokie Boulevard |
| Address2 | Suite 350 |
| All Time High | 240.0 |
| All Time Low | 1.37 |
| Ask | 57.29 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 209,220 |
| Average Daily Volume3 Month | 226,346 |
| Average Volume | 226,346 |
| Average Volume10Days | 209,220 |
| Beta | 1.655 |
| Bid | 55.53 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 20.595 |
| City | Wilmette |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 56.22 |
| Current Ratio | 51.353 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 59.43 |
| Day Low | 56.22 |
| Debt To Equity | 0.178 |
| Display Name | Monopar Therapeutics |
| Earnings Timestamp | 1,774,638,000 |
| Earnings Timestamp End | 1,778,612,400 |
| Earnings Timestamp Start | 1,778,612,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 236,078,560 |
| Eps Current Year | -4.0521 |
| Eps Forward | -3.75762 |
| Eps Trailing Twelve Months | -1.85 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 56.4601 |
| Fifty Day Average Change | -0.24009705 |
| Fifty Day Average Change Percent | -0.0042525083 |
| Fifty Two Week Change Percent | 31.631935 |
| Fifty Two Week High | 105.0 |
| Fifty Two Week High Change | -48.78 |
| Fifty Two Week High Change Percent | -0.46457142 |
| Fifty Two Week Low | 28.4 |
| Fifty Two Week Low Change | 27.820002 |
| Fifty Two Week Low Change Percent | 0.97957754 |
| Fifty Two Week Range | 28.4 - 105.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,576,765,800,000 |
| Float Shares | 4,396,803 |
| Forward Eps | -3.75762 |
| Forward P E | -14.961598 |
| Free Cashflow | -8,196,891 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23686 |
| Held Percent Institutions | 0.83082 |
| Implied Shares Outstanding | 6,692,140 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,723,507,200 |
| Last Split Factor | 1:5 |
| Long Business Summary | Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois. |
| Long Name | Monopar Therapeutics Inc. |
| Market | us_market |
| Market Cap | 376,232,128 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_304391755 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -13,716,894 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 376,232,110 |
| Number Of Analyst Opinions | 14 |
| Open | 59.04 |
| Operating Cashflow | -12,201,291 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 847 388 0349 |
| Post Market Change | 0.37999725 |
| Post Market Change Percent | 0.6759111 |
| Post Market Price | 56.6 |
| Post Market Time | 1,776,460,823 |
| Previous Close | 57.7 |
| Price Eps Current Year | -13.874287 |
| Price Hint | 2 |
| Price To Book | 2.729789 |
| Profit Margins | 0.0 |
| Quick Ratio | 51.33 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -1.48 |
| Regular Market Change Percent | -2.56499 |
| Regular Market Day High | 59.43 |
| Regular Market Day Low | 56.22 |
| Regular Market Day Range | 56.22 - 59.43 |
| Regular Market Open | 59.04 |
| Regular Market Previous Close | 57.7 |
| Regular Market Price | 56.22 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 244,534 |
| Return On Assets | -0.103879996 |
| Return On Equity | -0.14224 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 6,692,140 |
| Shares Percent Shares Out | 0.2517 |
| Shares Short | 1,684,127 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,590,237 |
| Short Name | Monopar Therapeutics Inc. |
| Short Percent Of Float | 0.67050004 |
| Short Ratio | 8.96 |
| Source Interval | 15 |
| State | IL |
| Symbol | MNPR |
| Target High Price | 130.0 |
| Target Low Price | 100.0 |
| Target Mean Price | 112.78571 |
| Target Median Price | 112.0 |
| Total Cash | 140,399,040 |
| Total Cash Per Share | 20.98 |
| Total Debt | 245,489 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 62.08395 |
| Two Hundred Day Average Change | -5.863949 |
| Two Hundred Day Average Change Percent | -0.09445193 |
| Type Disp | Equity |
| Volume | 244,534 |
| Website | https://www.monopartx.com |
| Zip | 60,091 |